Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Total Current Liabilities (2016 - 2025)

Cytosorbents' Total Current Liabilities history spans 15 years, with the latest figure at $9.7 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $9.7 million for Q4 2025, down 1.18% from a year ago — trailing twelve months through Dec 2025 was $9.7 million (down 1.18% YoY), and the annual figure for FY2025 was $9.7 million, down 1.18%.
  • Total Current Liabilities for Q4 2025 was $9.7 million at Cytosorbents, down from $10.1 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $14.7 million in Q1 2022 to a low of $8.3 million in Q3 2024.
  • The 5-year median for Total Current Liabilities is $10.0 million (2023), against an average of $10.8 million.
  • The sharpest move saw Total Current Liabilities plummeted 36.22% in 2021, then skyrocketed 50.34% in 2022.
  • Year by year, Total Current Liabilities stood at $13.7 million in 2021, then dropped by 29.04% to $9.7 million in 2022, then surged by 44.48% to $14.0 million in 2023, then fell by 30.0% to $9.8 million in 2024, then decreased by 1.18% to $9.7 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $9.7 million, $10.1 million, and $9.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.